More than 40% of adults with no known heart disease had fatty deposits in heart arteries

Research Highlights:

• More than 40% of middle-aged adults with no known heart disease had signs of atherosclerosis, a buildup of fatty deposits that reduce blood flow to the heart, in a study of more than 25,000 adults in Sweden.
• In more than 5% of the people who had a buildup of fatty deposits, the atherosclerosis narrowed at least one artery by 50% or more.
• In nearly 2% of the people with artery deposits, the narrowing was so severe that blood flow was obstructed to large portions of the heart. 
• The most widely used testing for atherosclerosis is a cardiac CT scan for coronary artery calcification (CAC) scoring, and it did not always detect atherosclerosis in people who had no symptoms of clogged arteries.
• Noninvasive coronary computed tomography angiography (CCTA) detected atherosclerosis in the cases missed by CAC scoring.

Embargoed until 4 a.m. CT/5 a.m. ET Monday, Sept. 20, 2021

DALLAS, Sept. 20, 2021 — More than 40% of adults ages 50 to 64 years in Sweden without known heart disease were found to have some degree of atherosclerosis, according to a new study published today in the American Heart Association’s flagship journal Circulation.

Atherosclerosis, or the buildup of fatty deposits in blood vessels that supply blood to the heart, is a major cause of heart attacks. A widely used approach to screen people who are at risk for heart disease but who do not yet have symptoms is cardiac computed tomography, commonly known as a cardiac CT scan, for coronary artery calcification (CAC) scoring. The scan creates cross-sectional images of the vessels that supply blood to the heart muscle to measure the presence and density of calcium-containing plaque in the coronary arteries. Based on these scans, individuals are given a CAC “score” to estimate their risk for or extent of coronary artery disease. This score can be 0 to over 400. A CAC score of 400 or higher is associated with a high risk for having a heart attack, stroke or dying from either one within the next 10 years. However, CAC scoring can miss a percentage of people who are at risk for heart attack even though they have a zero CAC score.

“Measuring the amount of calcification is important, yet it does not give information about non-calcified atherosclerosis, which also increases heart attack risk,” said study author Göran Bergström, M.D., Ph.D., professor and senior consultant in clinical physiology in the department of molecular and clinical medicine at the University of Gothenburg’s Institute of Medicine in Gothenburg, Sweden.

Bergström and colleagues randomly recruited participants aged 50 – 64 years old from the Swedish census register from 2013 to 2018 as part of the Swedish CArdioPulmonary BioImage Study (SCAPIS). They report on data from 25,182 participants with no history of a prior heart attack or cardiac intervention who underwent both CAC scans and coronary computed tomography angiography (CCTA) scans . CCTA is a radiologic technique that gives a very detailed image of the inside of the arteries that supply the heart with blood. The researchers wanted to determine the prevalence of atherosclerosis in the general population without established heart disease, and how closely the CCTA findings correlated to CAC scores.

They found:

• CCTA detected some degree of atherosclerosis in more than 42% of the study participants.
• CCTA found that in 5.2% of those with atherosclerosis, the build-up obstructed blood flow through at least one coronary artery (out of three) by 50% or more.
• In nearly 2% of those found to have artery build-up, the atherosclerosis was even more severe. Blood flow was obstructed to the main artery that supplies blood to large portions of the heart, and in some cases, all three coronary arteries were obstructed.
• Atherosclerosis started an average of 10 years later in women compared to men.
• Atherosclerosis was 1.8 times more common in people ages 60-64 vs. those ages 50-54.
• Participants with higher levels of atherosclerosis seen by CCTA also had higher CAC scores.
• Of those with a CAC score of more than 400, nearly half had significant blockage, where more than 50% of the blood flow was obstructed in one of the coronary arteries.
• In those with a CAC score of zero, 5.5% had atherosclerosis detected by CCTA, and 0.4% had significant obstruction of blood flow.

“The current, 2019 American Heart Association/American College of Cardiology guideline for prevention of heart attacks states that adults with a zero CAC score and intermediate level of risk factors are at low risk of future heart attack. We found that 9.2% of people who fit that description had atherosclerosis in their coronary arteries visible by CCTA,” Bergström said. “One strength of CCTA is that not-yet calcified atherosclerosis can be detected. We found that 8.3% of the adults had one or more non-calcified plaques. Non-calcified atherosclerosis is believed to be more prone to cause heart attacks compared with calcified atherosclerosis.”

The AHA/ACC guideline Bergström mentions does not address the use of CCTA in heart attack prevention.

“It is important to know that silent coronary atherosclerosis is common among middle-aged adults, and it increases sharply with sex, age and risk factors,” according to Bergström. “A high CAC score means there is a high likelihood of having obstruction of the coronary arteries. However, more importantly, a zero CAC score does not exclude adults from having atherosclerosis, especially if they have many traditional risk factors of coronary disease.”

A limitation of the study is that it lacks follow-up information about how cardiovascular heart disease develops in this population, which makes it impossible to determine if these findings predict clinical heart disease in this population.

Co-authors are Margaretha Persson, M.D., Ph.D.; Martin Adiels, Ph.D.; Elias Björnson, Ph.D.; Carl Bonander, Ph.D.; Håkan Ahlström, M.D., Ph.D.; Joakim Alfredsson, M.D., Ph.D.; Oskar Angerås, M.D., Ph.D.; Göran Berglund, M.D., Ph.D.; Anders Blomberg, M.D., Ph.D.; John Brandberg, M.D., Ph.D.; Mats Börjesson, M.D., Ph.D.; Kerstin Cederlund, M.D., Ph.D.; Ulf de Faire, M.D., Ph.D.; Olov Duvernoy, M.D., Ph.D.; Örjan Ekblom, Ph.D.; Gunnar Engström, M.D., Ph.D.; Jan Engvall, M.D., Ph.D.; Erika Fagman, M.D., Ph.D.; Mats Eriksson, M.D., Ph.D.; David Erlinge, M.D., Ph.D.; Björn Fagerberg, M.D., Ph.D.; Agneta Flinck, M.D., Ph.D.; Isabel Goncalves, M.D., Ph.D.; Emil Hagström, M.D., Ph.D.; Ola Hjelmgren, M.D., Ph.D.; Lars Lind, M.D., Ph.D.; Eva Lindberg, M.D., Ph.D.; Per Lindqvist, Ph.D.; Johan Ljungberg, M.D., Ph.D.; Martin Magnusson, M.D., Ph.D.; Maria Mannila, M.D., Ph.D.; Hanna Markstad, M.D.; Moman A. Mohammad, M.D., Ph.D.; Fredrik Nystrom, M.D., Ph.D.; Ellen Ostenfeld, M.D., Ph.D.; Anders Persson, M.D., Ph.D.; Annika Rosengren, M.D., Ph.D.; Anette Sandström, M.D.; Anders Själander, M.D., Ph.D.; Magnus Sköld, M.D., Ph.D.; Johan Sundström, M.D., Ph.D.; Eva Swahn, M.D., Ph.D.; Stefan Söderberg, M.D., Ph.D.; Kjell Torén, M.D., Ph.D.; Carl Johan Östgren, M.D., Ph.D.; and Tomas Jernberg, M.D., Ph.D. Authors have reported no disclosures reported.

This study received funding from the Swedish Heart-Lung Foundation, the Knut and Alice Wallenberg Foundation, the Swedish Research Council and VINNOVA (Sweden’s Innovation agency), the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and the Stockholm County Council, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, and Uppsala University and University Hospital.

Additional Resources:

Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers, health insurance providers and the Association’s overall financial information are available here. 

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org , Facebook , Twitter or by calling 1-800-AHA-USA1. 

###

For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

Maggie Francis: Maggie.Francis@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org